Sign in

NCT07117721Not yet recruiting

Endoscopic Band Ligation for Type 2 Diabetes Mellitus (ENDOBAND-DM)

Evaluation of Endoscopic Band Ligation for Treatment of Type 2 Diabetes: A Single-Center Interventional Study

Source: ClinicalTrials.gov · Last updated 10 Sept 2026

Brief summary (registry, in English)

This is a pilot clinical study evaluating the safety and feasibility of Endoscopic Band Ligation (ENDOBAND-DM) applied to the second through fourth parts of the duodenum - from just distal to the ampulla of Vater to the ligament of Treitz - in patients with type 2 diabetes mellitus (T2DM). The goal is to induce mucosal remodeling in this duodenal segment, potentially enhancing gut hormone signaling and improving glycemic control. Participants will be monitored for changes in HbA1c, fasting glucose, and insulin sensitivity over 6-12 months.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
10 (estimated)
First submitted
5 Aug 2025
Start date
1 Jan 2027
Primary completion date
1 Jan 2029
Lead sponsor
El Katib Hospital
NCT number
NCT07117721

What you commit to

  • Study type: Interventional
  • Planned participants: 10
  • From 1 Jan 2027 to the primary completion date, 1 Jan 2029
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Use of insulin therapy
  • Previous bariatric or gastrointestinal surgery
  • Use of GLP-1 receptor agonists within 3 months prior to enrollment

Other illness

  • Diagnosis of type 1 diabetes mellitus
  • Known gastrointestinal obstruction, ulcers, or active GI bleeding
  • History of pancreatitis, biliary disease, or abnormal anatomy in duodenum
  • Severe comorbidities (e.g., uncontrolled cardiovascular disease, advanced kidney or liver disease)

Other

  • Pregnancy or breastfeeding
  • Inability or unwillingness to comply with the study protocol

Who the study is looking for

  • Age between 18 and 70 years
  • Confirmed diagnosis of type 2 diabetes mellitus
  • HbA1c between 7.5% and 10.5% at screening
  • Body Mass Index (BMI) between 27 and 40 kg/m²
  • Stable use of oral antidiabetic medications for ≥3 months prior to enrollment
  • Willingness to undergo endoscopic procedure and attend all follow-up visits
  • Signed informed consen

Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.